We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

EHA 2025: Early Data Support Tocilizumab Use to Enable Outpatient Talquetamab Dosing in R/R Multiple Myeloma

Source: Pharmacy Times articles Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma. Read More

NCCN Flash Update: Linvoseltamab Added as Preferred Regimen After 4 Prior Therapies for Multiple Myeloma

Source: Pharmacy Times articles The National Comprehensive Cancer Network (NCCN) has released multiple myeloma guidelines version 2.2026 to include linvoseltamab as a preferred treatment for heavily pretreated patients, highlighting its intravenous formulation, dosing...

Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma

Source: Myeloma : nature.com subject feeds Post Content Read More

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma

Source: Myeloma : nature.com subject feeds Post Content Read More
Latest Data

Latest Publications

Treatment-related cognitive changes in multiple myeloma: A systematic review and meta-analysis

J Geriatr Oncol. 2025 Jul 19;16(7):102321. doi: 10.1016/j.jgo.2025.102321. Online ahead of print....

Spinal intradural lesion as manifestation of multiple myeloma: Illustrative case and systematic review of literature

Surg Neurol Int. 2025 Jun 20;16:247. doi: 10.25259/SNI_249_2025. eCollection 2025. ABSTRACT...

Comparison of MRI, [18F]FDG-PET/CT, and [18F]FDG-PET/MRI for Initial Staging of Multiple Myeloma: A Systematic Review and Meta-analysis

Clin Nucl Med. 2025 Jul 8. doi: 10.1097/RLU.0000000000006048. Online ahead of print. ABSTRACT...

Email

info@myeloma360.com